Allostera Pharma Secures Series A Financing
TechFinance.ca News Service
Wednesday July 8, 2009
Allostera Pharma Inc. today announced the closing of a $17 million Series A round of financing with iNovia Capital,...
[ ... to read the whole article, subscription is required ... ]
... ... clinical studies and begin human clinical testing of its lead Allosteramer™, APG2305, a novel drug candidate for trea...
To read this or any other article, or trial test our database, please try
our 7 days or 1 month subscription,
Click Here for Details.
Copyright © 2003-2010 TFmedia Corporation. All rights
reserved.
Any copying, republication or redistribution of TFmedia
content, including
by framing or similar means, is expressly prohibited without prior
written consent.
Company Deals and People
|
Date |
Title |
Type |
2009/7/7 |
Cedric Bisson |
Director |
2009/7/7 |
Ela Borenstein |
Director |
2009/7/7 |
Isabelle Dufresne |
Director |
2009/7/7 |
Jamie Stiff |
Director |
2009/7/7 |
Allostera Pharma Closes Series A Financing |
Financing |
2009/7/7 |
Jean-Paul Castaigne |
Director |
2009/7/7 |
Bogdan Dziurzynski |
Director |
2009/6/11 |
Mark Kaufmann, President & CEO |
Management |
2008/7/8 |
Carl Nicolino, VP, Corporate & Business Development |
Management |
2008/7/8 |
Shawn Barney, VP, Preclinical Development |
Management |
2005/7/8 |
Christiane Quiniou, co-founder, Scientific Director |
Management |
2005/7/8 |
Sylvain Chemtob, co-founder, Chief Scientific Officer |
Management |
|
|
|
Allostera Pharma Inc.
Privately-held
» To this firm page « (subscriber only)
1155 Boulevard René-Lévesque Ouest, Suite 2701
Montreal, QC
H3B 2K8
Tel: (514) 800-0480
Fax: (514) 371-4440
http://www.allostera.com
Sector - Biotechnology, Biopharmaceuticals
Business Description
Allostera Pharma Inc. is a biopharmaceutical developing an entirely new class of drugs, called Allosteramers™. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field.
|
|
Company News
|
Allostera Pharma Secures Series A Financing 2009/7/8
|
|
